Adiponectin Is a Component of the Inflammatory Cascade in Rheumatoid Arthritis.

adiponectin bone marrow infrapatellar fat pad rheumatoid arthritis synoviocytes

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
12 May 2022
Historique:
received: 02 04 2022
revised: 05 05 2022
accepted: 10 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Adiponectin is a secretory protein of adipocytes that plays an important role in pathological processes by participation in modulating the immune and inflammatory responses. The pro-inflammatory effect of adiponectin is observed in rheumatoid arthritis (RA). In this study, we examined adiponectin plasma levels and the expression of adiponectin in bone marrow tissue samples, synovium samples, and infrapatellar fat pad samples from patients with osteoarthritis (OA) and RA. Additionally we examined the expression of adiponectin receptors AdipoR1 and AdipoR2 in synovium samples and infrapatellar fat pad samples from patients with OA and RA. We also assessed the correlations between adiponectin plasma concentrations, adiponectin expression in bone marrow, synovium, infrapatellar fat pad, and plasma levels of selected cytokines. We found increased expression of adiponectin in synovium samples and infrapatellar fat pad samples from patients with RA as compared to patients with OA. There were no statistically significant differences of adiponectin plasma levels and adiponectin expression in bone marrow tissue samples between OA and RA patients. There were no differences in the expression of AdipoR1 and AdipoR2 at the mRNA level in synovial tissue and the infrapatellar fat pad between RA and OA patients. However, in immunohistochemical analysis in samples of the synovial membrane from RA patients, we observed very strong expression of adiponectin in intima cells, macrophages, and subintimal fibroblasts, such as synoviocytes, vs. strong expression in OA samples. Very strong expression of adiponectin was also noted in adipocytes of Hoffa's fat pad of RA patients. Expression of AdipoR1 was stronger in RA tissue samples, while AdipoR2 expression was very similar in both RA and OA samples. Our results showed increased adiponectin expression in the synovial membrane and Hoffa's pad in RA patients compared to that of OA patients. However, there were no differences in plasma adiponectin concentrations and its expression in bone marrow. The results suggest that adiponectin is a component of the inflammatory cascade that is present in RA. Pro-inflammatory factors enhance the expression of adiponectin, especially in joint tissues-the synovial membrane and Hoffa's fat pad. In turn, adiponectin also increases the expression of further pro-inflammatory mediators.

Identifiants

pubmed: 35628866
pii: jcm11102740
doi: 10.3390/jcm11102740
pmc: PMC9143302
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Minister of Science and Higher Education
ID : 002/RID/2018/19.

Références

Rheumatology (Oxford). 2012 Sep;51(9):1571-9
pubmed: 22596210
Osteoarthritis Cartilage. 2008 Sep;16(9):1101-9
pubmed: 18261936
Biomolecules. 2021 Feb 21;11(2):
pubmed: 33669910
Ann Rheum Dis. 2006 Sep;65(9):1198-201
pubmed: 16414972
Biochem Biophys Res Commun. 2000 Nov 11;278(1):250-7
pubmed: 11071880
Arthritis Res Ther. 2012 Dec 27;14(6):229
pubmed: 23270711
Scand J Rheumatol. 2008 Jul-Aug;37(4):260-8
pubmed: 18612926
Arthritis Rheum. 2009 Jul;60(7):1906-14
pubmed: 19565493
Int J Mol Sci. 2017 Jun 21;18(6):
pubmed: 28635626
Clin Rheumatol. 2015 Jun;34(6):1025-30
pubmed: 25750183
Exp Mol Med. 2012 Jul 31;44(7):440-7
pubmed: 22549135
Front Immunol. 2021 Feb 01;11:569883
pubmed: 33597943
J Endocrinol Invest. 2002 Nov;25(10):855-61
pubmed: 12508947
Front Immunol. 2021 Mar 18;12:626310
pubmed: 33815378
Adv Rheumatol. 2018 Aug 15;58(1):25
pubmed: 30657068
Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):25-31
pubmed: 24417943
Arthritis Care Res (Hoboken). 2021 Sep 24;:
pubmed: 34558809
Clin Exp Rheumatol. 2020 Jan-Feb;38(1):11-18
pubmed: 31025923
Clin Endocrinol (Oxf). 2013 Aug;79(2):204-10
pubmed: 22963459
Cells. 2021 Oct 01;10(10):
pubmed: 34685605
Exp Mol Med. 2014 Jan 17;46:e72
pubmed: 24434628
Biochimie. 2012 Oct;94(10):2157-63
pubmed: 22449616
Int J Mol Sci. 2019 Aug 22;20(17):
pubmed: 31443349
Curr Opin Clin Nutr Metab Care. 2007 Sep;10(5):571-5
pubmed: 17693739
Front Cardiovasc Med. 2019 Aug 14;6:116
pubmed: 31475160
Arthritis Res Ther. 2013;15(6):R210
pubmed: 24314299
Clin Rheumatol. 2022 Jan;41(1):255-264
pubmed: 34387761
J Mol Cell Biol. 2016 Apr;8(2):93-100
pubmed: 26993047
Adv Clin Chem. 2018;85:115-147
pubmed: 29655459
Rheumatol Ther. 2020 Sep;7(3):473-516
pubmed: 32734482
J Leukoc Biol. 2006 Apr;79(4):803-8
pubmed: 16434692
Front Genet. 2021 Sep 24;12:670282
pubmed: 34630505
Arthritis Res Ther. 2010;12(4):135
pubmed: 20804569
Int J Rheum Dis. 2018 Mar;21(3):664-672
pubmed: 28205390
Int J Mol Sci. 2020 Feb 12;21(4):
pubmed: 32059381
Semin Arthritis Rheum. 2009 Jun;38(6):420-7
pubmed: 18395775
J Clin Med. 2021 Jun 25;10(13):
pubmed: 34201946
Cytokine Growth Factor Rev. 2013 Feb;24(1):83-9
pubmed: 22910140
Int J Mol Sci. 2021 Nov 12;22(22):
pubmed: 34830137
Sci Rep. 2020 Jan 31;10(1):1564
pubmed: 32005896
Rheumatol Int. 2010 Apr;30(6):731-7
pubmed: 19597733
Med Tr Prom Ekol. 2013;(1):38-41
pubmed: 23785809
Sci Rep. 2022 Feb 8;12(1):2092
pubmed: 35136158
Clin Exp Rheumatol. 2017 May-Jun;35(3):406-414
pubmed: 28079506
J Cell Biochem. 2011 May;112(5):1431-40
pubmed: 21321996

Auteurs

Małgorzata Łączna (M)

Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Patrycja Kopytko (P)

Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Marta Tkacz (M)

Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Katarzyna Zgutka (K)

Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Michał Czerewaty (M)

Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Maciej Tarnowski (M)

Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Dariusz Larysz (D)

Department of Trauma and Orthopaedic Surgery, 109 Military Hospital, Piotra Skargi 9-11, 70-965 Szczecin, Poland.

Rafał Tkacz (R)

Department of Trauma and Orthopaedic Surgery, 109 Military Hospital, Piotra Skargi 9-11, 70-965 Szczecin, Poland.

Daniel Kotrych (D)

Department of Orthopaedics, Traumatology and Orthopaedic Oncology, Pomeranian Medical University, Unii Lubelskiej 1, 71-252 Szczecin, Poland.

Katarzyna Piotrowska (K)

Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Krzysztof Safranow (K)

Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland.

Karolina Łuczkowska (K)

Department of General Pathology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Bogusław Machaliński (B)

Department of General Pathology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Andrzej Pawlik (A)

Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.

Classifications MeSH